(Sildenafil citrate + testosterone) is under clinical development by Freya Pharma Solutions and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect (Sildenafil citrate + testosterone)’s likelihood of approval (LoA) and phase transition for Female Hypoactive Sexual Desire Disorder took place on 21 Nov 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their (Sildenafil citrate + testosterone) Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
(Sildenafil citrate + testosterone) overview
Sildenafil citrate in a fixed dose combination with testosterone (Lybrido) is under development for the treatment of female sexual dysfunction and hypoactive sexual desire disorder. The drug candidate is administered orally and sublingually. The drug candidate is a fixed-combination with an inner core of sildenafil with a polymeric time delay coating and an outer polymeric coating containing testosterone. Sildenafil citrate targets enzyme phosphodiesterase 5 (PDE5) and testosterone targets androgen receptor.
Freya Pharma Solutions overview
Freya Pharma Solutions (Freya) is a biotech business focused on the discovery of effective pharmacological therapeutics for female sexual interest/arousal problem in late-stage clinical trials (FSIAD). Freya is headquartered in Amsterdam, North Holland, The Netherlands.
Quick View (Sildenafil citrate + testosterone) LOA Data
|Highest Development Stage|